Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | PMM2 | O15305 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732116 | 0.80 | PTPN1 (1.00) | PTPN1PTPN2SLC40A1LMNANPC1 | |
| SCHEMBL1731402 | 0.78 | PTPN1 (0.96) | PTPN1PTPN2SLC40A1LMNANPC1 | |
| SCHEMBL6689304 | 0.78 | PTPN1 (0.81) | PTPN1PTPN2SLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL28044909 | 0.76 | PTPN1 (0.48) | PTPN1PTPN2SLC6A2SLC6A4 | |
| SCHEMBL2936379 | 0.76 | PTPN1 (0.70) | PTPN1PTPN2 | |
| SCHEMBL1688153 | 0.75 | PTPN1 (0.66) | PTPN1HSP90AA1PMM2MPIPHOSPHO1 | |
| SCHEMBL1731203 | 0.75 | PTPN1 (0.66) | PTPN1PTPN2SLC40A1MPI | |
| SCHEMBL643464 | 0.75 | PTPN1 (0.66) | PTPN1PTPN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3573712 | 0.75 | PTPN1 (0.53) | PTPN1PTPN2SLC40A1 | |
| Potassium SCHEMBL2937328 | 0.75 | PTPN1 (0.69) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1594497-B1 | SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERTEX PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | PTPN1 3634/4885HSP90AA1 2091/4885PTPN2 3361/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 23/4885HSP90AA1 2838/4885PTPN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.